Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | LPL | P06858 | 2/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.34 |
| ▸ | MMP1 | P03956 | 3/20 | 0.34 |
| ▸ | MMP7 | P09237 | 3/20 | 0.34 |
| ▸ | MMP12 | P39900 | 3/20 | 0.34 |
| ▸ | MMP13 | P45452 | 3/20 | 0.34 |
| ▸ | ACE | P12821 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3458150 | 0.84 | ENPP2 (0.36) | CTSKLPLLIPGALDH1A1POLB | |
| SCHEMBL5952263 | 0.77 | KDM4E (0.37) | CNR2LIPGKDM4E | |
| SCHEMBL7467180 | 0.75 | PCSK9 (0.37) | PCSK9CTSKALDH1A1POLBCYP3A4 | |
| SCHEMBL3234105 | 0.75 | PCSK9 (0.38) | PCSK9KDM4E | |
| SCHEMBL28918401 | 0.73 | CTSK (0.40) | CTSKALDH1A1CA2 | |
| SCHEMBL5952719 | 0.70 | PCSK9 (0.40) | PCSK9KDM4E | |
| SCHEMBL1128562 | 0.70 | PCSK9 (0.58) | PCSK9LPLLIPGALDH1A1CYP3A4 | |
| SCHEMBL14844285 | 0.70 | LTA4H (0.44) | CNR2CTSK | |
| SCHEMBL21599141 | 0.70 | L3MBTL1 (0.34) | ALDH1A1CYP3A4 | |
| SCHEMBL2653923 | 0.69 | PCSK9 (0.56) | PCSK9LPLLIPGALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7038070-B2 | Preparation of preparing substituted indanones | BASELL POLYOLEFINE GMBH (DE) | 2006-05-02 | — | — | US | disclosed |
| US-6963017-B2 | Preparation of preparing substituted indanones | BASELL POLYOLEFINE GMBH (DE) | 2005-11-08 | — | — | US | disclosed |
| US-20050176987-A1 | Method for producing vinyl, aryl and heteroaryl acetic acids and derivatives thereof | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2005-08-11 | — | — | US | disclosed |
| EP-0968158-B1 | METHOD OF PREPARING SUBSTITUTED INDANONES, THE SUBSTITUTED INDANONES AND METALLOCENES PREPARED THEREFROM | BASELL POLYOLEFINE GMBH (DE) | 2005-08-10 | — | — | EP | disclosed |
| US-20050033076-A1 | Preparation of preparing substituted indanones | EQUISTAR CHEMICALS, LP | 2005-02-10 | — | — | US | disclosed |
| US-20030009046-A1 | Preparation of preparing substituted indanones | EQUISTAR CHEMICALS, LP | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176987-A1 | Method for producing vinyl, aryl and heteroaryl acetic acids and derivatives thereof | HDHD5, PAH, AHR | PCSK9 4289/4885CNR2 1549/4885CTSK 3853/4885 |
| US-20050033076-A1 | Preparation of preparing substituted indanones | CYP1A2, CYP2J2, IDH3A | PCSK9 3742/4885CNR2 2769/4885CTSK 1812/4885 |
| US-20030009046-A1 | Preparation of preparing substituted indanones | CYP1A2, CYP1B1, CYP1A1 | PCSK9 3869/4885CNR2 2819/4885CTSK 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.